Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy

Hager Mohamed; Theodore Gurrola; Rachel Berman; Mackenzie Collins; Ilker K Sariyer; Michael R Nonnemacher; Brian Wigdahl

doi:10.3389/fimmu.2021.816515

Back

Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy

Journal article

Open access

Peer reviewed

Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy

Hager Mohamed, Theodore Gurrola, Rachel Berman, Mackenzie Collins, Ilker K Sariyer, Michael R Nonnemacher and Brian Wigdahl

Frontiers in immunology, v 12, pp 816515-816515

2021

DOI: https://doi.org/10.3389/fimmu.2021.816515

PMID: 35126374

Featured in Collection : UN Sustainable Development Goals @ Drexel

Files and links (1)

url

https://doi.org/10.3389/fimmu.2021.816515View

Published, Version of Record (VoR)CC BY V4.0, Open

Abstract

Anti-HIV Agents - pharmacology

Anti-HIV Agents - therapeutic use

Biomarkers

Carrier Proteins

CCR5 Receptor Antagonists - pharmacology

CCR5 Receptor Antagonists - therapeutic use

Combined Modality Therapy

Disease Management

Disease Progression

Disease Susceptibility

Gene Expression Regulation

HIV Infections - drug therapy

HIV Infections - genetics

HIV Infections - metabolism

HIV Infections - virology

HIV-1 - drug effects

HIV-1 - physiology

Humans

Lymphocytes - drug effects

Lymphocytes - immunology

Lymphocytes - metabolism

Macrophages - drug effects

Macrophages - immunology

Macrophages - metabolism

Molecular Targeted Therapy

Protein Binding

Receptors, CCR5 - chemistry

Receptors, CCR5 - genetics

Receptors, CCR5 - metabolism

Signal Transduction

Treatment Outcome

Globally, human immunodeficiency virus type 1 (HIV-1) infection is a major health burden for which successful therapeutic options are still being investigated. Challenges facing current drugs that are part of the established life-long antiretroviral therapy (ART) include toxicity, development of drug resistant HIV-1 strains, the cost of treatment, and the inability to eradicate the provirus from infected cells. For these reasons, novel anti-HIV-1 therapeutics that can prevent or eliminate disease progression including the onset of the acquired immunodeficiency syndrome (AIDS) are needed. While development of HIV-1 vaccination has also been challenging, recent advancements demonstrate that infection of HIV-1-susceptible cells can be prevented in individuals living with HIV-1, by targeting C-C chemokine receptor type 5 (CCR5). CCR5 serves many functions in the human immune response and is a co-receptor utilized by HIV-1 for entry into immune cells. Therapeutics targeting CCR5 generally involve gene editing techniques including CRISPR, CCR5 blockade using antibodies or antagonists, or combinations of both. Here we review the efficacy of these approaches and discuss the potential of their use in the clinic as novel ART-independent therapies for HIV-1 infection.

Metrics

11 Record Views

53 citations in Web of Science

50 citations in Scopus

Details

Title: Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy
Creators: Hager Mohamed - Drexel University
Theodore Gurrola - Department of Microbiology and Immunology, Center for Molecular Virology and Translational Neuroscience, Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, PA, United States
Rachel Berman - Department of Microbiology and Immunology, Center for Molecular Virology and Translational Neuroscience, Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, PA, United States
Mackenzie Collins - Department of Microbiology and Immunology, Center for Molecular Virology and Translational Neuroscience, Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, PA, United States
Ilker K Sariyer - Temple University
Michael R Nonnemacher - Drexel University
Brian Wigdahl - Drexel University
Publication Details: Frontiers in immunology, v 12, pp 816515-816515
Publisher: Frontiers
Grant note: R01 MH110360 / NIMH NIH HHS P30 MH092177 / NIMH NIH HHS UM1 AI164568 / NIAID NIH HHS T32 MH079785 / NIMH NIH HHS
Resource Type: Journal article
Language: English
Academic Unit: Microbiology and Immunology
Web of Science ID: WOS:000751019700001
Scopus ID: 2-s2.0-85124071557
Other Identifier: 991019168496504721

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types: Domestic collaboration
Web of Science research areas: Immunology

Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy

Files and links (1)

Abstract

Metrics

Details

UN Sustainable Development Goals (SDGs)

InCites Highlights

Drexel University Social media